DELIVER at the HFSA

The DELIVER team presented 5 new papers at the Heart Failure Society of America in Washington, DC.

• Dapagliflozin in Heart Failure with Improved Ejection Fraction The DELIVER Trial presented by Orly Vardeny

• Time to Clinical Benefit of Dapagliflozin in Patients with HF with Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of DELIVER presented by Muthiah Vaduganathan

• Effect of Dapagliflozin on Cause-Specific Mortality in Patients with Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER presented by Akshay Desai

• Blood Pressure, Dapagliflozin, and Cardiovascular Outcomes In Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER presented by Senthil Selvaraj

• Translating the Findings of the DELIVER Trial to Medicare Beneficiaries Hospitalized for HF in the United States presented by Muthiah Vaduganathan